Aclaris Therapeutics (ACRS) EBITDA Margin (2017 - 2026)
Aclaris Therapeutics (ACRS) posted quarterly EBITDA Margin of 1111.82% for Q1 2026, up 13106.0% year-over-year from N/an in Q1 2025, and up 36.67% quarter-over-quarter from 1755.52% in Q4 2025.
Aclaris Therapeutics (ACRS) EBITDA Margin (2017 - 2026) Analysis & Trends
Aclaris Therapeutics' EBITDA Margin history runs 10 years deep, the most recent figure standing at 1111.82% for Q1 2026.
- In Q1 2026, EBITDA Margin rose 13106.0% year-over-year to 1111.82%; the TTM figure through Mar 2026 stood at 961.91% (down 16832.0% YoY), while the FY2025 annual figure was 975.91%, down 21773.0% from the prior year.
- EBITDA Margin for Q1 2026 stood at 1111.82%, up from 1755.52% in the prior quarter.
- The five-year high for EBITDA Margin was 23.03% in Q4 2023, with the low at 1755.52% in Q4 2025.
- The 5-year median for EBITDA Margin is 1035.9% (2025), against an average of 861.89%.
- Peak annual rise in EBITDA Margin reached 123753 bps in 2024, while the deepest fall reached 105910 bps in 2024.
- Aclaris Therapeutics' EBITDA Margin stood at 375.07% in 2022, then jumped by 94 bps to 23.03% in 2023, then plunged by 4598 bps to 1082.13% in 2024, then sank by 62 bps to 1755.52% in 2025, then jumped by 37 bps to 1111.82% in 2026.
- Business Quant data shows ACRS's EBITDA Margin at 1111.82% in Q1 2026, 1755.52% in Q4 2025, and 519.82% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,569,866.34% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | Aclaris Therapeutics | 808.18 Mn | 716.63 Mn | 1.41 Mn | -1,487.91% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1,487.91% |
| Mar 31, 2026 | -1,111.82% |
| Dec 31, 2025 | -1,755.52% |
| Sep 30, 2025 | -519.82% |
| Jun 30, 2025 | -1,035.90% |
| Mar 31, 2025 | -1,242.89% |
| Dec 31, 2024 | -1,082.13% |
| Sep 30, 2024 | -240.93% |
| Jun 30, 2024 | -464.71% |
| Mar 31, 2024 | -789.45% |
| Dec 31, 2023 | -23.03% |
| Sep 30, 2023 | -340.20% |
| Jun 30, 2023 | -1,702.25% |
| Mar 31, 2023 | -1,183.47% |
| Dec 31, 2022 | -375.07% |
| Sep 30, 2022 | -109.76% |
| Jun 30, 2022 | -1,373.95% |
| Mar 31, 2022 | -1,301.24% |
| Dec 31, 2021 | -1,525.18% |
| Sep 30, 2021 | -1,223.33% |